TABLE 1.

Case studies of de novo psoriasis following COVID‐19 vaccination in literature

Authors	Number of patient(s) a	Gender of patient(s)	Age of patient(s)	Vaccine regimen	Day(s) of onset	Psoriasis subtype(s)	Severity	History of COVID‐19	Treatment(s) (response)
Wei et al. 3	1	Male	89	First dose: mRNA‐1273 Second dose: mRNA‐1273	24 after second dose	N/A	60% BSA affected	No	Ixekizumab acitretin 25 mg (resolved)
Lehmann et al. 7	1	Female	79	First dose: BNT162b2	10 after first dose	(mainly) guttate	N/A possibly mild	N/A	calcipotriol/betamethasone ointment + UVB (N/A)
Song et al. 8	1	Female	23	First dose: BNT162b2	Two after first dose	Guttate	N/A; possibly mild	N/A	Topical calcipotriol/betamethasone (significantly improved)
Nagrani et al. 9	1	Male	65	First dose: AZD1222 b Second dose: AZD1222	10 after second dose	Plaque	30% BSA	N/A	Apremilast, antihistamines and emollients (well‐responsed)
Elamin et al. 10	1	Female	66	First dose: AZD1222 b	21 after first dose	Pustular	Extensive, possibly moderate‐to‐severe	No	Topical steroid, Acitretin 20 mg qd (resolved)
Our case reports	3	Two males One female	51, 68, and 73	Three AZD1222 doses; one BNT162b2 dose; and mixed one dose of BNT162b2 after two doses of mRNA‐1273	7 days after the first AZD1222; 30 days after the first BNT162b2 dose; 30 days after the third BNT162b2 dose in a mixed regimen	One guttate Two plaque	Mild	Yes: 1 No: 2	Topical calcipotriol/betamethasone antihistamines

^a Included new‐onset psoriasis only.

^b Also known as ChAdOx1 nCoV‐19.